LAGUNA HILLS, CA, April 19, 2017 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received the 2017 Buzz of BIO “Pipelines of Promise” award ahead of the 2017 BIO International Convention. Each year BIO International opens voting for its Buzz of BIO award in two categories, “Pipelines of Promise” and “Technologies of Tomorrow.” The winners are announced ahead of BIO International’s annual convention.
As the winner of the “Pipelines of Promise” award, PharmaCyte will have an opportunity to give a company presentation in the BIO Business Forum in front of industry leaders at the 2017 BIO International Convention, which is being held this year at the San Diego Convention Center in San Diego, California. Also, obtaining the award provides PharmaCyte with access to global biotech and pharma leaders through the BIO One-on-One Partnering™ system, exposure to industry thought-leaders with over 1,500 education sessions and unparalleled networking opportunities with 16,000+ industry leaders from 76 countries. The BIO One-on-One Partnering™ system is the most efficient way to do business in the biotech and pharma industry without traveling all over the world. BIO’s system makes it easy to search for and identify potential partners and request meetings with prospective biotech investors and senior business development executives.
The BIO International Convention attracts 16,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. The Convention brings together a wide spectrum of life science and application areas, including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.
The 2017 BIO International Convention is the world’s largest biotechnology gathering with tens of thousands of people expected to attend this year’s Convention. It features 1,800 exhibitors and 55 regional and international pavilions, with 8 specialized product focus zones. The BIO International Convention allows companies like PharmaCyte the opportunity to interact with influential decision makers and high-level executives that come to the Convention to discover new therapies in the biotechnology sector, evaluate emerging technologies and form new partnerships.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide comes in contact with the encapsulated cells they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects. 2
In addition to developing a novel therapy for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a “bio-artificial pancreas” for purposes of insulin production.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements because of the impact of several risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
PharmaCyte Biotech, Inc.
Investor Relations Department